Technology | January 16, 2013

Lantheus Introduces Low-Enriched Uranium (LEU) Tc-99m Generator

Supports long-term strategy to eliminate use of highly enriched uranium (HEU)-produced molybdenum and technetium

Lantheus LEU TechneLite generator Mo-99 Nuclear Imaging Radiopharmeceuticals

January 16, 2013 — Lantheus Medical Imaging Inc. has added a low-enriched uranium (LEU) TechneLite (technetium Tc 99m Generator) generator to the its nuclear imaging product portfolio. Lantheus’ LEU TechneLite generator is the first technetium-99m (Tc-99m) generator in the United States that contains molybdenum-99 (Mo-99) produced from at least 95 percent LEU. With greater access to LEU Mo-99 through its supply chain diversification strategy, Lantheus can now move closer to its goal of eventually eliminating Highly Enriched Uranium (HEU)-sourced Mo-99 from its supply chain. Lantheus’ first LEU TechneLite generator was shipped on Jan. 7, 2013.

With the introduction of the LEU TechneLite generator, Lantheus fully supports the U.S. government’s global nuclear security strategy to encourage reliable supplies of medical radioisotopes produced from non-HEU sources. On Jan. 2, 2013, President Obama signed into law the American Medical Isotopes Production Act of 2011 (AMIPA) as part of the 2013 National Defense Authorization Act. The AMIPA encourages the domestic production of LEU Mo-99 and provides for the eventual prohibition of the export of HEU from the United States. In addition, the Centers for Medicare and Medicaid Services (CMS) recently stipulated in the 2013 final Medicare payment rules, for Medicare Hospital Outpatients, that CMS will provide incremental reimbursement for every Tc-99m diagnostic dose produced from non-HEU sourced Mo-99. Lantheus’ LEU TechneLite generator satisfies the new reimbursement requirements under the CMS 2013 rules.

“We are pleased to be the first company to offer a Tc-99m generator produced using at least 95 percent LEU,” said Don Kiepert, president and chief executive officer of Lantheus Medical Imaging. “As leaders in nuclear medicine, an important component of our global sourcing strategy is to increase our use of LEU-sourced Mo-99 with a goal of 100 percent by 2016. Our TechneLite generator is used in many critical diagnostic imaging procedures, including scans of the heart, brain, bone, kidneys and some types of tumors. The introduction of our LEU TechneLite generator expands our nuclear medicine product portfolio and meets CMS’ new reimbursement requirements for Medicare Hospital Outpatients in 2013, while supporting the government’s non-proliferation goal of moving away from the use of HEU in the production of medical isotopes.”

Mo-99 is the parent isotope of Tc-99m, which is the radioisotope most widely used for nuclear imaging tests. Tc-99m is used in approximately 15 million doses in the United States annually. As a leader in the radiopharmaceutical business, Lantheus has secured the most globally diversified and balanced Mo-99 supply chain in the industry, and receives the medical isotope from four of the five major processors and seven of the eight associated reactors.

In 2012, Lantheus announced expanded access to LEU-sourced Mo-99 with an extended agreement with NTP Radioisotopes in South Africa. Under the five-year agreement, Lantheus will receive an increasing supply of Mo-99 produced from LEU targets from NTP Radioisotopes (NTP) and Australian Nuclear Science and Technology Organisation (ANSTO). Additionally, Lantheus announced continued supply of Mo-99 from Nordion, which will be used in the production of the company’s non-LEU TechneLite generators.

“We continue to be committed to providing a stable, balanced and reliable supply of Mo-99 to our customers,” said Cyrille Villeneuve, chief commercial officer of Lantheus Medical Imaging. “Our gradual transition to LEU-sourced Mo-99 and the addition of the LEU TechneLite generator ensures that our customers will have continued access to Tc-99m, now and in the future. We believe our LEU strategy gives us a strong position in the generator market and provides a differentiated offering for our customers.”

For more information: www.technelite.com

Related Content

Study Demonstrates First Human Application of Novel PET Tracer for Prostate Cancer

Transaxial 11Csarcosine hybrid PET/CT showed a (triangulated) adenocarcinoma in the transition zone of the anterior right prostate gland on PET (A), CT (B), and a separately obtained T2?weighted MR sequence (C) with resulting PET/MRI registration (D). Image courtesy of M. Piert et al., University of Michigan, Ann Arbor, Mich.

News | Radiopharmaceuticals and Tracers | August 16, 2017
In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the...
PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
Novel PET Tracer Detects Small Blood Clots

PET images (MIP 0-60 min) of three Cynomolgus monkeys. Strong signals are detected at the sites where inserted catheters had roughened surfaces. Almost no other background signal is visible. Only accumulation in the gallbladder becomes visible at the bottom of the image. Credit: Piramal Imaging GmbH, Berlin Germany.

News | PET Imaging | July 07, 2017
July 7, 2017 — Blood clots in veins a
Dual-Agent PET/MR With Time of Flight Detects More Cancer

Tc-99m MDP bone scan (left) is negative for osseous lesions. NaF/FDG PET/MRI (right and second slide) confirms absence of bone metastases, but shows liver metastases. Image courtesy of Stanford University.

News | PET-MRI | June 20, 2017
Simultaneous injections of the radiopharmaceuticals fluorine-18 fluorodeoxyglucose (18F-FDG) and 18F-sodium fluoride (...
Lantheus and GE Healthcare Sign Agreement for Worldwide Development, Commercialization of Flurpiridaz F-18
News | Radiopharmaceuticals and Tracers | May 22, 2017
May 22, 2017 — Lantheus Holdings Inc., parent company of Lantheus Medical Imaging Inc., and GE Healthcare announced t
FALCON Trial of Fluciclovine PET/CT Imaging Stops Recruitment after Successful Interim Analysis
News | Radiopharmaceuticals and Tracers | May 15, 2017
Blue Earth Diagnostics announced that the Trial Steering Committee recommended further recruitment be stopped in the...
Australian Team Finds New Method for Producing PET Radiotracers in Higher Radiochemical Yields
News | Radiopharmaceuticals and Tracers | April 28, 2017
April 28, 2017 — Researchers at the Australian Nuclear Science and Technology Organisation (ANSTO) have led the devel
News | Prostate Cancer | April 24, 2017
April 24, 2017 — Cancer Targeted Technology recently announced it is focusing on small molecules that target pivotal
University of Missouri Research Reactor Files to Start U.S. Production of Medical Isotopes
News | Radiopharmaceuticals and Tracers | April 13, 2017
The University of Missouri Research Reactor (MURR) and its partners Nordion and General Atomics (GA), announced in...
IBA Molecular and Mallinckrodt Nuclear Medicine Merge to Become Curium
News | Radiopharmaceuticals and Tracers | April 11, 2017
IBA Molecular announced that it has merged with previous acquisition Mallinckrodt Nuclear Medicine LLC to form the new...
Overlay Init